Anzeige
❌
Mehr »
Donnerstag, 08.10.2026 - Börsentäglich über 12.000 News
Patent bis 2039: Ist das der nächste große Wachstumstreiber für diese Small-Cap-Aktie?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A0D9T1 | ISIN: US2521311074 | Ticker-Symbol: DC4
Tradegate
08.10.26 | 19:18
75,00 Euro
-0,53 % -0,40
1-Jahres-Chart
DEXCOM INC Chart 1 Jahr
5-Tage-Chart
DEXCOM INC 5-Tage-Chart
RealtimeGeldBriefZeit
75,0075,2020:41
75,0075,2020:20

Aktuelle News zur DEXCOM Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
09:34Medtech-Branche: Citi bestätigt Abbott und Dexcom als Top-Picks33
FrDXCM Report Highlights CGM Growth Opportunity in Type 2 Diabetes Care5
28.09.DexCom, Inc.: Dexcom Publishes New Report During EASD 2026 on Type 2 Diabetes Revealing Critical Opportunity for Global Diabetes Care464New global State of Type 2 Report uncovers three interconnected challenges in Type 2 diabetes care: health literacy, technology literacy and systemic access.1 New partnership reinforces...
► Artikel lesen
15.09.Dexcom CFO to expand into COO role4
15.09.Dexcom's CFO Jereme Sylvain To Take Addl. Role Of COO407WASHINGTON (dpa-AFX) - DexCom Inc. (DXCM), a medical device company, announced the promotion of Jereme Sylvain to the role of Chief Operating Officer in addition to his duties as Chief Financial...
► Artikel lesen
14.09.Dexcom promotes CFO Jereme Sylvain to dual COO role2
DEXCOM Aktie jetzt für 0€ handeln
14.09.DexCom expands CFO's role to COO2
14.09.Here's Why You Should Retain DexCom Stock in Your Portfolio for Now4
10.09.DEXCOM INC - 8-K, Current Report1
08.09.DexCom Stock: Is DXCM Underperforming the Healthcare Sector?3
25.08.Abbott vs. DexCom: Which CGM Stock Is the Better Buy Now?17
17.08.Biotech Stocks At 52-Week Highs - Eton Pharmaceuticals +44%, DexCom, Oruka Therapeutics, Concentra Group Holdings Parent, AtaiBeckley986INDIANAPOLIS (dpa-AFX) - The following biotech stocks reached 52-week highs on August 14, 2026, following positive quarterly reports or an announced upcoming acquisition. Eton Pharmaceuticals...
► Artikel lesen
12.08.Can DexCom's Raised 2026 Outlook Sustain Stronger Margin Momentum?4
12.08.Is DXCM Stock Worth Buying as Growth Improves but Valuation Stretches?3
12.08.DXCM Stock Up Nearly 35% YTD: Will the Uptrend Continue in the Rest of 2026?3
12.08.DXCM Rallies 52.5% in 3 Months. Can the Stock Keep Climbing From Here?9
12.08.Biotech Stocks At 52-Week Highs - Alamar Biosciences +30% on Q2 Reports, Dyne Therapeutics, Cullinan Therapeutics, DexCom, Cardinal Health2.687WASHINGTON (dpa-AFX) - The following biotech stocks reached a 52-week high on August 11, 2026, driven up by key catalysts such as positive quarterly or full year reports.Alamar Biosciences Inc....
► Artikel lesen
05.08.Insulet sends Tandem, DexCom lower after guidance cut18
03.08.Watch Amazon, Dexcom, Corteva, and Coinbase12
03.08.Piper Sandler reiterates Overweight on DexCom stock on FDA pilot5
1 2 3 4 5 Weiter >>
108 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1